Primary Polydipsia (Dipsogenic Type)
The most likely diagnosis is primary polydipsia, specifically the dipsogenic subtype, characterized by a pathologically lowered osmotic threshold for thirst that drives excessive fluid intake despite attempts at restriction. 1
Clinical Reasoning
The key diagnostic feature here is marked thirst when attempting evening fluid restriction while taking desmopressin. This clinical presentation creates a critical distinction between different polyuria-polydipsia syndromes:
Why This Points to Primary Polydipsia
Polydipsia is an absolute contraindication to desmopressin treatment because combining the antidiuretic effect of desmopressin with excessive fluid intake causes water intoxication, hyponatremia, and potentially life-threatening seizures or convulsions. 1
The FDA drug label explicitly states: "Desmopressin acetate is contraindicated in patients with polydipsia" due to increased risk of severe hyponatremia. 2
The Dipsogenic Subtype Specifically
Recent research identifies dipsogenic polydipsia (DP) as a distinct variety characterized by selective diminution of the osmotic threshold for thirst, leading to polydipsia and subsequent hypotonic polyuria. 3 This condition:
- Occurs in patients without underlying psychiatric illness (distinguishing it from psychogenic/compulsive water drinking)
- Closely mimics central diabetes insipidus clinically
- Features a low thirst threshold that makes fluid restriction intolerable
- Shows high AVP release threshold on osmotic stimulation testing
Critical Safety Concern
The patient is at immediate risk of severe hyponatremia if desmopressin continues while they cannot restrict fluids. The FDA warns that desmopressin combined with excessive fluid intake can cause:
- Water intoxication
- Hyponatremia
- Seizures
- Coma
- Respiratory arrest
- Death 2
Multiple case reports document severe hyponatremia (sodium as low as 113 mEq/L) in patients taking desmopressin who cannot adequately restrict fluids. 4
Diagnostic Approach
To confirm dipsogenic polydipsia versus partial central diabetes insipidus:
- Measure serum sodium and osmolality immediately - check for hyponatremia
- Perform osmotic stimulation test with objective assessment of:
- Threshold for thirst sensation
- AVP (or copeptin) release threshold
- Expected findings in dipsogenic polydipsia:
- Low osmotic threshold for thirst (patient feels thirsty at lower serum osmolality than normal)
- High threshold for AVP release
- This separates DP from both central DI and psychogenic polydipsia 3
Management Implications
Desmopressin must be discontinued immediately if the patient cannot restrict evening fluids to ≤200 mL (6 ounces) from 1 hour before until 8 hours after administration. 1, 2
However, if confirmed as dipsogenic polydipsia through proper testing, desmopressin may actually be used successfully - but only with careful titration to keep serum osmolality marginally below the patient's abnormally low thirst threshold, thereby providing symptomatic relief without triggering the pathological thirst drive. 3 This requires:
- Frequent sodium monitoring (within 1 week, at 1 month, then periodically)
- Target serum osmolality just below the patient's measured thirst threshold
- Close supervision and patient education
The paradox is that unlike psychogenic polydipsia where desmopressin is absolutely contraindicated, in true dipsogenic polydipsia, desmopressin can be therapeutic when properly managed because it addresses the underlying polyuria without the same hyponatremia risk seen in compulsive water drinking. 3